We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App





JNJ Collaborates with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development

By HospiMedica International staff writers
Posted on 23 Mar 2020
Print article
Illustration
Illustration
Johnson & Johnson’s (New Brunswick, NJ, USA) Janssen Pharmaceutical Companies (Beerse, Belgium) have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA) to support the development of a preventive vaccine candidate for COVID-19. The companies have commenced preclinical testing of multiple vaccine prospects, with the aim of identifying a COVID-19 vaccine candidate for clinical trials by the end of the month.

Janssen’s vaccine program will use the Janssen AdVac and PER.C6 technologies that provide the ability to rapidly upscale production of an optimal vaccine candidate. The company is leveraging its proven vaccine technology that it is also using to develop its investigational Ebola (which also utilizes its MVA-BN technology), Zika, RSV and HIV vaccines. Research and collaboration on preclinical work for Johnson & Johnson’s Zika and HIV vaccine candidates at the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center was foundational to developing these vaccines.

Johnson & Johnson’s efforts to expedite development and production of a vaccine are enhanced by the existing COVID-19 vaccine collaborations between Janssen and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the US Department of Health & Human Services. In addition to Janssen’s efforts to develop a vaccine candidate, the company is working closely with global strategic partners to screen its library of antiviral molecules to accelerate the discovery of potential COVID-19 treatments and provide relief for people around the world. Janssen is optimistic that, in collaboration with multiple global strategic partners, it can initiate a Phase 1 clinical study of a potential vaccine candidate by the end of the year. In parallel to these efforts, Janssen is preparing to upscale production and manufacturing capacities to levels required to meet global public health vaccination needs.

“It is critical to work with the best scientific minds as we look to rapidly identify and develop solutions to the COVID-19 outbreak,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. “We are grateful for talented and experienced collaboration partners like Dan Barouch and his team at BIDMC. By mobilizing our collective resources, we believe we can leverage the top science and cutting-edge capabilities to respond to this pandemic.”

“We are currently evaluating a series of potential vaccine candidates for COVID-19. This collaboration with Janssen is aimed at the development of a COVID-19 vaccine that would allow for rapid development, large-scale manufacturing, and global delivery,” said Dan Barouch, M.D., Ph.D., Director of the Center for Virology and Vaccine Research at BIDMC and the Ragon Institute.

Related Links:
Johnson & Johnson
Janssen Pharmaceutical Companies
Beth Israel Deaconess Medical Center (BIDMC)



Print article

Channels

Business

view channel
Illustration

Omnia Health Live Unites Global Healthcare Community Through New Virtual Experience

Omnia Health Live, a virtual healthcare event, has brought the global healthcare community together on a scale never seen before through a new experience delivered entirely online. The virtual healthcare... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.